Shire  (SHPG) shares were up more than 6% premarket after the company announced the successful 26-week drug trial of lanadelumab, a drug that treats hereditary angiodema, a rare disease that causes swelling in the extremities, gastrointestinal tract, and upper airways.

About 90% the of the study's patients, which was conducted on patients aged 12 years and older, completed the trial and 96% of those that completed chose to roll over into the long-term study. 

"We are extremely encouraged by these topline Phase 3 results. We have nearly a decade of experience and a strong portfolio and pipeline in HAE and believe these data demonstrate high potential for transforming the way patients living with this condition are treated," CEO Flemming Ornskov, M.D., M.P.H. said. 

Jim Cramer and Real Money columnists discuss the latest from President Donald Trump and the GOP efforts to repeal and replace the Affordable Care Act. See which stocks they are discussing and get his insights or analysis with a free trial subscription to Real Money.

More from Stocks

The Stakes Are High for FAANG Stocks This Time Around

The Stakes Are High for FAANG Stocks This Time Around

Profit From the Good Side of Bad Selloffs: An Illustration

Profit From the Good Side of Bad Selloffs: An Illustration

Data Regulation on FAANG's Could Just Be Underway: Cramer's Investing Teach-in

Data Regulation on FAANG's Could Just Be Underway: Cramer's Investing Teach-in

Your Need to Know - Forward Look

Your Need to Know - Forward Look

A Guide to Investing in the Fast-Emerging Cannabis Industry

A Guide to Investing in the Fast-Emerging Cannabis Industry